TCRX · TScan Therapeutics, Inc. · Share Buybacks
$0.32
+0.00 (+0.79%)
At close · Sep 11
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, substantial doubt about the Company's ability to continue as a going concern exists. ... These conditions raise substantial doubt about the Company's ability to continue as a going concern. ... Therefore, substantial doubt about the Company's ability to continue as a going concern has not been alleviated.”View the 10-Q filed Aug 12, 2026
Market Cap
$21.72M
Shares
67.78M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2023-05-16 | — | $75,000,000 | — | — | 10-Q , filed 2026-08-12 |
Key facts
CIK
1783328
CUSIP
89854M101
13F (30d)
26 filings
26 filers
Visit website
Investor relations